Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen

Journal of Immunology

Volumn 184, Issue 8, 2010, Pages 4269-4275

  Bridle, Byram W ^a   Li, Jian ^a   Jiang, Shucui ^a   Chang, Ruby ^a   Lichty, Brian D ^a   Bramson, Jonathan L ^a   Wan, Yonghong ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DOPACHROME TAUTOMERASE; CANCER VACCINE; DOPACHROME ISOMERASE; ISOMERASE; TUMOR ANTIGEN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BRAIN DAMAGE; BRAIN PROTECTION; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEMYELINATION; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENCEPHALITIS; FEMALE; HISTOPATHOLOGY; INTRACRANIAL TUMOR; MELANOMA B16; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR REJECTION; VITILIGO; ADENOVIRUS; ANIMAL; BRAIN TUMOR; C57BL MOUSE; EXPERIMENTAL MELANOMA; GENE TARGETING; GENETICS; GRAFT REJECTION; IMMUNOLOGY; INFLAMMATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; GENE TARGETING; GRAFT REJECTION; INFLAMMATION; INJECTIONS, INTRAVENTRICULAR; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; VITILIGO;

EID: 77952776857     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901447     Document Type: Article

References (46)

1. Mitchell, D. A., P. E. Fecci, and J. H. Sampson. 2008. Immunotherapy of malignant brain tumors. Immunol. Rev. 222: 70-100.
2. Blattman, J. N., and P. D. Greenberg. 2004. Cancer immunotherapy: a treatment for the masses. Science 305: 200-205.
3. Schietinger, A., M. Philip, and H. Schreiber. 2008. Specificity in cancer immunotherapy. Semin. Immunol. 20: 276-285.
4. Mufson, R. A. 2006. Tumor antigen targets and tumor immunotherapy. Front. Biosci. 11: 337-343.
5. Malyankar, U. M. 2007. Tumor-associated antigens and biomarkers in cancer and immune therapy. Int. Rev. Immunol. 26: 223-247.
6. Engelhard, V. H., T. N. Bullock, T. A. Colella, S. L. Sheasley, and D. W. Mullins. 2002. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol. Rev. 188: 136-146.
7. + T lymphocytes. Proc. Natl. Acad. Sci. USA 96: 2982-2987.
8. + T cells. J. Exp. Med. 198: 569-580.
9. + T cells and local inflammation: implications for the pathophysiology of vitiligo. J. Invest. Dermatol. 124: 144-150.
10. Chianese-Bullock, K. A., E. M. Woodson, H. Tao, S. A. Boerner, M. Smolkin, W. W. Grosh, P. Y. Neese, P. Merrill, G. R. Petroni, and C. L. Slingluff, Jr. 2005. Autoimmune toxicities associated with the administration of anti-tumor vaccines and low-dose interleukin-2. J. Immunother. 28: 412-419.
11. Luiten, R. M., E. W. Kueter, W. Mooi, M. P. Gallee, E. M. Rankin, W. R. Gerritsen, S. M. Clift, W. J. Nooijen, P. Weder, W. F. van de Kasteele, et al. 2005. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J. Clin. Oncol. 23: 8978-8991.
12. Ram, M., and Y. Shoenfeld. 2007. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann. N. Y. Acad. Sci. 1110: 410-425.
13. Attia, P., G. Q. Phan, A. V. Maker, M. R. Robinson, M. M. Quezado, J. C. Yang, R. M. Sherry, S. L. Topalian, U. S. Kammula, R. E. Royal, et al. 2005. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23: 6043-6053.
14. Turk, M. J., J. D. Wolchok, J. A. Guevara-Patino, S. M. Goldberg, and A. N. Houghton. 2002. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 188: 122-135.
15. Lane, C., J. Leitch, X. Tan, J. Hadjati, J. L. Bramson, and Y. Wan. 2004. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res. 64: 1509-1514. (Pubitemid 38235624)
16. Bronte, V., E. Apolloni, R. Ronca, P. Zamboni, W. W. Overwijk, D. R. Surman, N. P. Restifo, and P. Zanovello. 2000. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 60: 253-258.
17. Hodge, J. W., D. W. Grosenbach, W. M. Aarts, D. J. Poole, and J. Schlom. 2003. Vaccine therapy of established tumors in the absence of autoimmunity. Clin. Cancer Res. 9: 1837-1849.
18. Lang, K. S., M. Recher, T. Junt, A. A. Navarini, N. L. Harris, S. Freigang, B. Odermatt, C. Conrad, L. M. Ittner, S. Bauer, et al. 2005. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 11: 138-145.
19. Chi, D. D., R. E. Merchant, R. Rand, A. J. Conrad, D. Garrison, R. Turner, D. L. Morton, and D. S. Hoon. 1997. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am. J. Pathol. 150: 2143-2152.
20. Prins, R. M., S. K. Odesa, and L. M. Liau. 2003. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 63: 8487-8491.
21. Jiao, Z., Z. G. Zhang, T. J. Hornyak, A. Hozeska, R. L. Zhang, Y. Wang, L. Wang, C. Roberts, F. M. Strickland, and M. Chopp. 2006. Dopachrome tautomerase (Dct) regulates neural progenitor cell proliferation. Dev. Biol. 296: 396-408.
22. Madajewicz, S., C. Karakousis, C. R. West, J. Caracandas, and A. M. Avellanosa. 1984. Malignant melanoma brain metastases: review of Roswell Park Memorial Institute experience. Cancer 53: 2550-2552. (Pubitemid 14102500)
23. Liu, G., H. T. Khong, C. J. Wheeler, J. S. Yu, K. L. Black, and H. Ying. 2003. Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J. Immunother. 26: 301-312. (Pubitemid 36858714)
24. + T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J. Immunol. 176: 200-210.
25. Parkhurst, M. R., E. B. Fitzgerald, S. Southwood, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1998. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58: 4895-4901.
26. + T-cell helper epitope. Cancer Res. 67: 6459-6467.
27. Collins, T. J. 2007. ImageJ for microscopy. Biotechniques 43(Suppl. 1): S25-S30.
28. Karl, T., R. Pabst, and S. von Hörsten. 2003. Behavioral phenotyping of mice in pharmacological and toxicological research. Exp. Toxicol. Pathol. 55: 69-83.
29. Crawley, J. N., and R. Paylor. 1997. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm. Behav. 31: 197-211.
30. Miyakawa, T., E. Yared, J. H. Pak, F. L. Huang, K. P. Huang, and J. N. Crawley. 2001. Neurogranin null mutant mice display performance deficits on spatial learning tasks with anxiety related components. Hippocampus 11: 763-775. (Pubitemid 34065506)
31. Walsh, R. N., and R. A. Cummins. 1976. The Open-Field Test: a critical review. Psychol. Bull. 83: 482-504.
32. Leitch, J., K. Fraser, C. Lane, K. Putzu, G. J. Adema, Q. J. Zhang, W. A. Jefferies, J. L. Bramson, and Y. Wan. 2004. CTL-dependent and -independent anti-tumor immunity is determined by the tumor not the vaccine. J. Immunol. 172: 5200-5205. (Pubitemid 38542016)
33. + T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. J. Immunol. 172: 857-863.
34. Koon, H., and M. Atkins. 2006. Autoimmunity and immunotherapy for cancer. N. Engl. J. Med. 354: 758-760.
35. Gilboa, E. 2001. The risk of autoimmunity associated with tumor immunotherapy. Nat. Immunol. 2: 789-792.
36. Caspi, R. R. 2008. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat. Rev. Immunol. 8: 970-976.
37. Steitz, J., C. M. Britten, T. Wölfel, and T. Tüting. 2006. Effective induction of antimelanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol. Immunother. 55: 246-253.
38. Uchi, H., R. Stan, M. J. Turk, M. E. Engelhorn, G. A. Rizzuto, S. M. Goldberg, J. D. Wolchok, and A. N. Houghton. 2006. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv. Immunol. 90: 215-241.
39. Kaufman, H. L., and J. D. Wolchok. 2006. Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. J. Clin. Oncol. 24: 2230-2232.
40. Gogas, H., J. Ioannovich, U. Dafni, C. Stavropoulou-Giokas, K. Frangia, D. Tsoutsos, P. Panagiotou, A. Polyzos, O. Papadopoulos, A. Stratigos, et al. 2006. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354: 709-718.
41. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulationwith anti-tumor lymphocytes. Science 298: 850-854.
42. O, I., M. Blaszczyk-Thurin, C. T. Shen, and H. C. Ertl. 2003. A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma. Cancer Gene Ther. 10: 678-688.
43. Mrass, P., and W. Weninger. 2006. Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Immunol. Rev. 213: 195-212.
44. Walker, P. R., T. Calzascia, V. Schnuriger, N. Scamuffa, P. Saas, N. de Tribolet, and P. Y. Dietrich. 2000. The brain parenchyma is permissive for full anti-tumor CTL effector function, even in the absence of CD4 T cells. J. Immunol. 165: 3128-3135.
45. Engelhardt, B., and R. M. Ransohoff. 2005. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26: 485-495. (Pubitemid 41139258)
46. Broder, H., A. Anderson, T. J. Kremen, S. K. Odesa, and L. M. Liau. 2003. MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor. J. Neurooncol. 64: 21-30. (Pubitemid 36992457)